% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • alabamatigers11u alabamatigers11u May 18, 2011 11:09 PM Flag

    VICL listed as buyout target in article posted today

    Vical Incorporated (VICL): Vical researches and develops vaccine therapies for the prevention and treatment of cancer and other infectious diseases, with five active clinical and preclinical programs in development. Vical share prices have been fluctuating between $2.88 and $3.30 this month, with good news coming recently with European patent approval for treatment TransVax.

    We're high on Vical's prospects because of its use of DNA vaccines, which offer less risk and more efficient manufacturing compared to traditional pathogen-induced vaccines. The technology allows Vical to provide vaccines in weeks instead of months or years without ever having to handle the pathogen.

    Based on Vical's effective products in the pipeline, lack of debt, and reserves of cash to last it through 2012, we see Vical as a strong buy. We think shares could reach closer to $6 by year's end with initiation of Phase III trials for multiple drugs

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.02+0.22(+5.79%)May 27 4:00 PMEDT